Objective: To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-Infected patients on HAART. Method: This was a cross-sectional multicenter cohort study in eight tertiary Clinical Centers of Northern and Central Italy. Consecutive outpatients taking HAART were enrolled from August 2000 to March 2001. They completed a self-administered questionnaire for the evaluation of signs of MOA and the self-reported adherence to drugs. Main outcome measures were MOA according to the Multicenter AIDS Cohort Study (MACS) definition and adherence to drugs. Results: One hundred seventy-five persons were enrolled into the study. Median CD4 cell count was 522 (interquartile range [IQR] 306-720); 35% of people had undetectable HIV RNA. Patients had been taking HAART for a median of 53 months (IQR 33-62). Among enrolled patients, 83 (47%) had a diagnosis of self-reported MOA; 57 of them reported body changes of more than 12 months duration. Forty persons (23%) self-reported nonadherence in the previous week. Mean time on HAART was 48.7 months (SD = 19.7) for people with MOA and 42.1 months (SD = 21.8) for those without MOA (p =.043). The odds of adherence for people with MOA was 2.36 times (95% Cl 1.11-5.00) higher than for people without MOA. On multivariate analysis, being older and female, having an undetectable HIV RNA, longer duration on HAART, and self-reported adherence were independently associated with the presence of MOA. In people with MOA, adherence seems to decrease over time. Conclusion: Longer time on HAART and self-reported adherence were correlated to MOA. MOA was also associated with older age and female gender.

Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART / Guaraldi, Giovanni; R., Murri; G., Orlando; E., Orlandi; G., Sterrantino; M., Borderi; C., Grosso; A. M., Cattelan; Nardini, Giulia; Beghetto, Barbara; A., Antinori; Esposito, Roberto; A. W., Wu. - In: HIV CLINICAL TRIALS. - ISSN 1528-4336. - STAMPA. - 4 (2):(2003), pp. 99-106. [10.1310/W1QF-C9X9-9PFT-88JK]

Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART.

GUARALDI, Giovanni;NARDINI, Giulia;BEGHETTO, Barbara;ESPOSITO, Roberto;
2003-01-01

Abstract

Objective: To evaluate the association between adherence to drugs and morphologic alterations (MOA) in a cohort of HIV-Infected patients on HAART. Method: This was a cross-sectional multicenter cohort study in eight tertiary Clinical Centers of Northern and Central Italy. Consecutive outpatients taking HAART were enrolled from August 2000 to March 2001. They completed a self-administered questionnaire for the evaluation of signs of MOA and the self-reported adherence to drugs. Main outcome measures were MOA according to the Multicenter AIDS Cohort Study (MACS) definition and adherence to drugs. Results: One hundred seventy-five persons were enrolled into the study. Median CD4 cell count was 522 (interquartile range [IQR] 306-720); 35% of people had undetectable HIV RNA. Patients had been taking HAART for a median of 53 months (IQR 33-62). Among enrolled patients, 83 (47%) had a diagnosis of self-reported MOA; 57 of them reported body changes of more than 12 months duration. Forty persons (23%) self-reported nonadherence in the previous week. Mean time on HAART was 48.7 months (SD = 19.7) for people with MOA and 42.1 months (SD = 21.8) for those without MOA (p =.043). The odds of adherence for people with MOA was 2.36 times (95% Cl 1.11-5.00) higher than for people without MOA. On multivariate analysis, being older and female, having an undetectable HIV RNA, longer duration on HAART, and self-reported adherence were independently associated with the presence of MOA. In people with MOA, adherence seems to decrease over time. Conclusion: Longer time on HAART and self-reported adherence were correlated to MOA. MOA was also associated with older age and female gender.
4 (2)
99
106
Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART / Guaraldi, Giovanni; R., Murri; G., Orlando; E., Orlandi; G., Sterrantino; M., Borderi; C., Grosso; A. M., Cattelan; Nardini, Giulia; Beghetto, Barbara; A., Antinori; Esposito, Roberto; A. W., Wu. - In: HIV CLINICAL TRIALS. - ISSN 1528-4336. - STAMPA. - 4 (2):(2003), pp. 99-106. [10.1310/W1QF-C9X9-9PFT-88JK]
Guaraldi, Giovanni; R., Murri; G., Orlando; E., Orlandi; G., Sterrantino; M., Borderi; C., Grosso; A. M., Cattelan; Nardini, Giulia; Beghetto, Barbara; A., Antinori; Esposito, Roberto; A. W., Wu
File in questo prodotto:
File Dimensione Formato  
Guaraldi HIV Clin Trials 2003.pdf

non disponibili

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 263.09 kB
Formato Adobe PDF
263.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/305388
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 32
social impact